The majority of women at high risk of developing breast cancer decide against prophylactic treatment with tamoxifen, suggest findings of a new study funded by Cancer Research UK and published in Breast Cancer Research and Treatment.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.